The European Medicines Agency has recommended that two first-of-a-kind treatments be approved across the EU – Amryt Pharma’s Filsuvez (birch bark extract), for epidermolysis bullosa, and Roche’s Lunsumio (mosunetuzumab), for follicular lymphoma.
Filsuvez, a topical gel that was rejected in the US in February, is now set to be authorized for use...








